Ovarian cancer

Ovarian cancer is an extremely deadly disease characterised by an abnormal growth of ovarian, fallopian tube or primary peritoneal tissue with malignant tumours spreading beyond the site of origin into the peritoneal cavity and affecting the organs within (e.g. the spleen, bowel mesentery and liver). There were nearly 300,000 new cases of ovarian cancer worldwide in 2018 [World Cancer Research Fund]. For most patients, surgery is the first line of treatment. This is usually followed by chemotherapy and typically devastating side effects including hair loss, nausea, vomiting, appetite loss, pain, weakened immunity and fatigue.
Treated with chemotherapy
Survive over 10 years
Projected rise in incidence

Engineering ovarian cancer therapeutics

We are developing #Oncojans, a promising new class of drug-loaded particles, designed to precisely target and gain entry to cancer cells. In the tumours, they slowly release drugs at the point of need whilst sparing healthy tissue. Early preclinical studies for #BMT101, our lead ovarian cancer candidate, compared to the clinical standard of care, Taxol®, have shown very encouraging results including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, doubling of median survival and loss of toxicity. #BMT101 and future engineered #Oncojans could be transformational in the treatment of cancer patients.
Increased efficacy
The targeted active therapeutic should focus and sustain release drugs at tumours in order to prolong patient survival through efficacy gains.
Reduced toxicity
There should be less active therapeutic distributed or released at healthy tissues significantly limiting the side effects endured by patients.
More patients
#Oncojans should enable more patients, including those that are frail and would not normally tolerate chemotherapy, to be eligible for treatment.

News

Team

Dr Keith Powell
Dr Keith Powell

Chairman

Keith has been in biotechnology since it started. Having worked for GSK and ICI/Zeneca in genetics/molecular biology he led several large groups including discovery and finally running the patent group. He then worked at Maxygen on the West Coast leading the small molecule group through the IPO and growing a business that eventually spun out as ‘Codexis’. On returning to the UK, Keith joined the Bloomsbury BioSeed Fund and Longbow Capital and acted as CEO for several portfolio companies. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry and Polytherics was built through organic growth since 2005 to be now part of the Abzena group of companies. Keith is currently chairman of Canbex, Intract, Oppilotech and has a range of other Board interests in the healthcare industry.

Dr Davidson Ateh
Dr Davidson Ateh

CEO

Davidson is an entrepreneurial bioengineer with a successful track record of managing and financing disruptive early stage technology projects. He has an interdisciplinary background in the physical and life sciences with a BEng in Biomedical Materials and a PhD in Bioengineering from Queen Mary University of London. He was a recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School. He is the CEO of BioMoti where he raised over £2.5 million in non-dilutive and risk capital including securing a number of alliances. He has progressed BioMoti’s innovative #Oncojan cancer therapeutics platform, leading on preclinical development, clinical planning, financial modelling, market research, commercial plans, business development, venture pitching, regulatory compliance, staff, team building, external contractors and partnerships with pharma companies.

Prof Joanne Martin
Prof Joanne Martin

NED

Jo is the Director of Academic Health Sciences (and Consultant Histopathologist) at Barts Health NHS Trust and Professor of Pathology at Queen Mary University of London. She was previously NHS National Clinical Director of Pathology and is currently the President of The Royal College of Pathologists. Jo has an international reputation in the study of diseases with over 115 publications including high impact journals such as Science and Nature. She is an experienced business leader (MA in Leadership) with a track record of running a large NHS Trust Division (£89 million budget per annum), delivering and commissioning a £40 million building, and 2 major IT system implementations (both over £1.3 million). She has an excellent understanding of technology transfer previously been an assessor of early stage technologies for Nikko Principal Investments Ltd. Jo is a co-inventor of the #Oncojan cancer therapeutics platform, co-founder and a non-executive Director on the board of BioMoti.

Get in touch

The QMB Innovation Centre | 42 New Road London E1 2AX | UK